UP!
| Industry | Drug Manufacturers - Other |
|---|---|
| Founded | 1988 |
| Headquarters | Palo Alto, California, United States |
|
Key people
|
Michael M. Wick M.D. ( Chief Medical Officer ) (Dec 31, 2012) |
|
Number of employees
|
17 (Dec 31, 2012) |
Michael M. Wick M.D.
( Chairman, Chief Executive Officer, and President)
Wendy K. Wee
( Principal Financial & Accounting Officer )
Telik, Inc. was set up in 1988 and was reverse merged into privately held MabVax in May 2014. The major drug of the company was TELINTRA, an investigational agent that was in development for the treatment of myelodysplastic syndrome (MDS) and idiopathic chronic neutropenia.
In 2007, a class action was filed against Telik, Inc., alleging that they made false and misleading statements about the Company’s business and prospects during the Class Period.
| 2007-09-28 | Initiated | BMO Capital Markets | Market Perform | $3 |
| 2007-06-05 | Downgrade | Wachovia | Outperform to Mkt Perform | |
| 2007-04-17 | Upgrade | Stifel Nicolaus | Sell to Hold | |
| 2007-04-17 | Upgrade | Janney Mntgmy Scott | Sell to Neutral | |
| 2007-01-03 | Downgrade | Bear Stearns | Outperform to Peer Perform |
| 2007-09-28 | Initiated | BMO Capital Markets | Market Perform | $3 |
| 2007-06-05 | Downgrade | Wachovia | Outperform to Mkt Perform | |
| 2007-04-17 | Upgrade | Stifel Nicolaus | Sell to Hold | |
| 2007-04-17 | Upgrade | Janney Mntgmy Scott | Sell to Neutral | |
| 2007-01-03 | Downgrade | Bear Stearns | Outperform to Peer Perform |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In TELK 0 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| Barry Richard J. | 85.03% (11847125) | TELK / |
| BLACK BEAR OFFSHORE MASTER FUND LP | 57.21% (7971542) | TELK / |
| EASTBOURNE CAPITAL MANAGEMENT LLC/CA | 11.00% (1532709) | TELK / |
| Livingston Philip O. Chief Science Officer | 1.84% (256554) | TELK / |
| Barry Richard | 1.75% (243800) | SRPT / TELK / |
| HANSEN JOHN DAVID President and CEO | 1.37% (190827) | TELK / |
| HANSON GREGORY P Chief Financial Officer | 0.82% (114307) | TELK / |
| Scholz Wolfgang W. VP of Antibody Discovery | 0.81% (113288) | TELK / |
| MAFFUID PAUL W Vice President | 0.72% (99877) | TELK / |
| EISENBERG JEFFREY F | 0.46% (64558) | TELK / |
| CANTRALL EDWARD W | 0.36% (50000) | TELK / |
| WICK MICHAEL M President, CEO and Chairman | 0.24% (33551) | TELK / |
| Cohen Kenneth M | 0.18% (24552) | ADMP / TELK / |
| Varvaro Thomas C | 0.17% (23063) | TELK / |
| MAIER PAUL V | 0.17% (23063) | APRI / PURE / SQNM / TELK / |
| von Morze Herwig | 0.16% (22000) | TELK / |
| Antonopoulos Jim J. former director | 0.15% (21258) | TELK / |
| Resnick Paul F VICE PRESIDENT, CBO | 0.13% (18333) | TELK / |
| HOFFMAN ROBERT | 0.03% (4438) | ARNA / CBMX / HRTX / TELK / |
| Ravetch Jeffrey V. | 0.02% (3086) | TELK / |
UM